Trials / Terminated
TerminatedNCT01581060
Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours
A Phase I/II, Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor WX-554 in Patients With Solid Tumours
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Heidelberg Pharma AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of part 1 of this study is to determine the optimal biological dose (OBD) and maximum tolerated dose (MTD) for WX-554 and the recommended dose/dose schedules for the chronic treatment in part 2. The aim of part 2 is to further determine the safety and tolerability of chronic treatment with WX-554.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | WX-554 | Capsules of WX-554 |
Timeline
- Start date
- 2012-03-01
- Primary completion
- 2014-04-01
- Completion
- 2014-04-01
- First posted
- 2012-04-19
- Last updated
- 2014-05-16
Locations
5 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01581060. Inclusion in this directory is not an endorsement.